Immunic, Inc.
IMUX
$1.12
-$0.03-2.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.01M | 18.09M | 17.51M | 16.87M | 16.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.05M | 95.80M | 93.65M | 95.85M | 99.22M |
| Operating Income | -98.05M | -95.80M | -93.65M | -95.85M | -99.22M |
| Income Before Tax | -100.51M | -96.90M | -95.31M | -97.92M | -93.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.51 | -96.90 | -95.31 | -97.92 | -93.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.51M | -96.90M | -95.31M | -97.92M | -93.61M |
| EBIT | -98.05M | -95.80M | -93.65M | -95.85M | -99.22M |
| EBITDA | -97.92M | -95.68M | -93.53M | -95.75M | -99.11M |
| EPS Basic | -1.01 | -1.24 | -1.51 | -1.84 | -2.11 |
| Normalized Basic EPS | -0.60 | -0.74 | -0.91 | -1.12 | -1.32 |
| EPS Diluted | -1.01 | -1.24 | -1.51 | -1.84 | -2.11 |
| Normalized Diluted EPS | -0.60 | -0.74 | -0.91 | -1.12 | -1.32 |
| Average Basic Shares Outstanding | 400.55M | 344.44M | 287.75M | 230.91M | 177.27M |
| Average Diluted Shares Outstanding | 400.55M | 344.44M | 287.75M | 230.91M | 177.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |